BR112022022524A2 - Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas - Google Patents

Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas

Info

Publication number
BR112022022524A2
BR112022022524A2 BR112022022524A BR112022022524A BR112022022524A2 BR 112022022524 A2 BR112022022524 A2 BR 112022022524A2 BR 112022022524 A BR112022022524 A BR 112022022524A BR 112022022524 A BR112022022524 A BR 112022022524A BR 112022022524 A2 BR112022022524 A2 BR 112022022524A2
Authority
BR
Brazil
Prior art keywords
baff
april
immunomodulatory
cell
proteins
Prior art date
Application number
BR112022022524A
Other languages
English (en)
Inventor
Dillon Stacey
Rixon Mark
Evans Lawrence
William DEMONTE Daniel
L Kuijper Joseph
L Peng Stanford
Swanson Ryan
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of BR112022022524A2 publication Critical patent/BR112022022524A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEÍNAS IMUNOMODULADORAS INIBIDORAS DE APRIL E BAFF COM E SEM UMA PROTEÍNA INIBIDORA DE CÉLULAS T E MÉTODOS DE USO DAS MESMAS. A presente invenção refere-se a proteínas imunomoduladoras que exibem atividade neutralizante de BAFF e APRIL (ou heterotrímeros BAFF/APRIL) sozinhos, ou também acopladas à inibição da coestimulação de células T. As proteínas imunomoduladoras fornecidas no presente documento incluem domínios variantes do antígeno de maturação de células B (BCMA) sozinho ou proteína imunomoduladora de múltiplos domínios que inibem respostas de células B e também podem inibir a coestimulação de células T. Também são fornecidas moléculas de ácidos nucleicos que codificam as proteínas imunomoduladoras. As proteínas imunomoduladoras fornecem utilidade terapêutica para uma variedade de doenças ou condições imunológicas. Também são fornecidas composições e métodos para fazer e usar tais proteínas.
BR112022022524A 2020-05-08 2021-05-07 Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas BR112022022524A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063022373P 2020-05-08 2020-05-08
US202063034361P 2020-06-03 2020-06-03
US202063080643P 2020-09-18 2020-09-18
PCT/US2021/031432 WO2021226553A2 (en) 2020-05-08 2021-05-07 April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022022524A2 true BR112022022524A2 (pt) 2022-12-13

Family

ID=76270049

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022022433A BR112022022433A2 (pt) 2020-05-08 2021-05-07 Proteínas imunomoduladoras inibitórias april e baff e métodos de uso das mesmas
BR112022022524A BR112022022524A2 (pt) 2020-05-08 2021-05-07 Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022022433A BR112022022433A2 (pt) 2020-05-08 2021-05-07 Proteínas imunomoduladoras inibitórias april e baff e métodos de uso das mesmas

Country Status (15)

Country Link
US (4) US20210388054A1 (pt)
EP (2) EP4146684A2 (pt)
JP (2) JP2023525033A (pt)
KR (2) KR20230029622A (pt)
CN (4) CN116903727A (pt)
AU (2) AU2021268033A1 (pt)
BR (2) BR112022022433A2 (pt)
CA (2) CA3178885A1 (pt)
CL (1) CL2022003104A1 (pt)
CO (1) CO2022017780A2 (pt)
IL (2) IL297981A (pt)
MX (2) MX2022013999A (pt)
PE (1) PE20230494A1 (pt)
TW (1) TW202208414A (pt)
WO (2) WO2021226551A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
JP2022539785A (ja) * 2019-12-24 2022-09-13 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途
EP4333869A1 (en) * 2021-05-07 2024-03-13 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023089500A1 (en) * 2021-11-17 2023-05-25 Aurinia Pharmaceuticals Inc. B cell activating factor (baff)-a proliferation inducing ligand (april) dual inhibitors
CA3236667A1 (en) * 2022-06-08 2023-12-14 Jianmin Fang Method for treating myasthenia gravis with taci-fc fusion protein
WO2024044721A1 (en) * 2022-08-25 2024-02-29 University Of Washington Injectable recombinant protein-based hydrogels for therapeutic delivery
WO2024077018A2 (en) * 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
WO2024120458A1 (zh) * 2022-12-07 2024-06-13 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白液体药物制剂

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
ATE248924T1 (de) 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69534702T2 (de) 1994-09-23 2006-08-24 The University Of British Columbia, Vancouver Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
PT784483E (pt) 1994-10-03 2001-05-31 Us Gov Health & Human Serv Composicao que compreende um virus recombinante que exprime um antigenio e um virus recombinante que exprime uma molecula imunoestimuladora
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
EP1746106A3 (en) 2000-04-27 2007-03-14 Biogen Idec MA Inc. Use of TACI as an anti-tumor agent
AU2001253920B2 (en) 2000-04-27 2006-03-16 Apoxis Sa Use of taci as an anti-tumor agent
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
KR20040030628A (ko) 2001-05-24 2004-04-09 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
PL377119A1 (pl) 2001-08-03 2006-01-23 Genentech, Inc. Peptydy TACIs i BR3 i ich zastosowanie
DK1461073T3 (da) 2001-11-30 2010-03-29 Us Gov Health & Human Serv Peptidagonister til prostataspecifikt antigen og anvendelser heraf
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003256836A1 (en) 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
WO2004033486A2 (en) 2002-10-11 2004-04-22 Zymogenetics, Inc. Production of homotrimeric fusion proteins
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1629001A2 (en) 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
BRPI0415709A (pt) 2003-10-20 2006-12-19 Biogen Idec Inc esquemas terapêuticos para antagonistas de baff
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
CN101987870B (zh) 2004-07-15 2013-07-03 赞科股份有限公司 优化的Fc变体
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2387312T3 (es) 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
MX2007005378A (es) 2004-11-04 2008-02-14 Genentech Inc Polipeptidos que ligan a baff y/o april.
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JP2009507777A (ja) 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1924286A4 (en) 2005-08-12 2010-01-13 Garvan Inst Med Res PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US7655439B2 (en) 2005-09-09 2010-02-02 Zymogenetics, Inc. Trimerizing polypeptides
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
CA2661872A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
FI2061803T4 (fi) 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
JP2010501622A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
JP2010516744A (ja) 2007-01-26 2010-05-20 メルク セローノ ソシエテ アノニム 油体技術を用いたＦｃ−融合タンパク質の精製
US8852591B2 (en) 2007-03-27 2014-10-07 Zymogenetics, Inc. Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease
SG182191A1 (en) * 2007-06-13 2012-07-30 Zymogenetics Inc Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2203465A1 (en) 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying an fc-containing protein
PL2219675T3 (pl) 2007-11-12 2014-04-30 Ares Trading Sa Formulacja dla białek fuzyjnych TACI-immunoglobulina
US20100239580A1 (en) 2007-11-12 2010-09-23 Area Trading S.A. Taci-immunoglobulin fusion proteins for treatment of optic neuritis
EP2219673A1 (en) 2007-11-12 2010-08-25 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
DK2222861T3 (en) 2007-12-11 2018-02-05 Univ North Carolina Chapel Hill POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
CA2720651C (en) 2008-05-01 2020-03-10 Zymogenetics, Inc. Levels of blys/april heterotrimers in serum and use in diagnostic methods
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
EP2435477A1 (en) 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
WO2011109280A1 (en) * 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN101851278B (zh) 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
US20110311548A1 (en) 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
JP6267512B2 (ja) 2010-09-10 2018-01-24 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 幹細胞培養培地および方法
CN102085368B (zh) 2011-01-19 2013-06-12 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗***性红斑狼疮药物的应用
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
CN105392801A (zh) 2013-03-15 2016-03-09 比奥根Ma公司 使用抗αvβ5抗体治疗和预防急性肾损伤
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
JP2017522312A (ja) 2014-07-15 2017-08-10 イミューン デザイン コーポレイション Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン
CA2990177A1 (en) 2015-06-25 2016-12-29 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
BR112018011781A2 (pt) * 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
EP3443000A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3442999A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CA3029197A1 (en) 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
KR20190099194A (ko) 2016-10-20 2019-08-26 알파인 이뮨 사이언시즈, 인코포레이티드 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018236995A2 (en) 2017-06-20 2018-12-27 Dana-Farber Cancer Institute, Inc. METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS
AU2018326805B2 (en) 2017-09-01 2023-11-30 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
MA50360A (fr) * 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
CA3078517A1 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
GB201720426D0 (en) 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
US20230101432A1 (en) 2018-01-03 2023-03-30 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
MX2020009051A (es) 2018-03-02 2020-12-03 Allogene Therapeutics Inc Receptores de citocina quimericos inducibles.
CN110522908A (zh) 2018-05-25 2019-12-03 荣昌生物制药（烟台）有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020028572A2 (en) 2018-08-01 2020-02-06 Unum Therapeutics Inc. ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
JP2022501361A (ja) 2018-09-19 2022-01-06 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
JP2022510276A (ja) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
WO2020214867A1 (en) 2019-04-17 2020-10-22 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
CN114728040A (zh) 2019-06-14 2022-07-08 科优基因公司 新型白介素-2变体及其双功能融合分子
EP4056232A4 (en) 2019-09-13 2023-09-13 Kyowa Kirin Co., Ltd. DCR3 VARIANT
BR112021025458A2 (pt) 2019-12-10 2022-06-21 Remegen Co Ltd Formulação farmacêutica, método de preparação e uso da mesma
JP2022539785A (ja) 2019-12-24 2022-09-13 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途

Also Published As

Publication number Publication date
TW202208414A (zh) 2022-03-01
CN116903727A (zh) 2023-10-20
JP2023525032A (ja) 2023-06-14
CA3178882A1 (en) 2021-11-11
WO2021226553A3 (en) 2022-04-28
CL2022003104A1 (es) 2023-07-14
US20210388054A1 (en) 2021-12-16
US11274140B2 (en) 2022-03-15
MX2022013998A (es) 2023-02-16
IL297980A (en) 2023-01-01
BR112022022433A2 (pt) 2022-12-13
PE20230494A1 (es) 2023-03-23
MX2022013999A (es) 2023-02-16
CN116194467A (zh) 2023-05-30
EP4146683A1 (en) 2023-03-15
CA3178885A1 (en) 2021-11-11
WO2021226551A1 (en) 2021-11-11
IL297981A (en) 2023-01-01
US20210363223A1 (en) 2021-11-25
US20230241168A1 (en) 2023-08-03
AU2021268033A1 (en) 2022-12-15
WO2021226553A2 (en) 2021-11-11
JP2023525033A (ja) 2023-06-14
KR20230029621A (ko) 2023-03-03
CO2022017780A2 (es) 2023-03-17
AU2021267276A1 (en) 2022-12-15
US20240218045A1 (en) 2024-07-04
CN117736297A (zh) 2024-03-22
KR20230029622A (ko) 2023-03-03
EP4146684A2 (en) 2023-03-15
CN115812077A (zh) 2023-03-17

Similar Documents

Publication Publication Date Title
BR112022022524A2 (pt) Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas
Grange et al. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-κB and MAPK pathways
BR112017020961A2 (pt) muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
Terragni et al. Notch signaling genes: myogenic DNA hypomethylation and 5-hydroxymethylcytosine
Secor et al. Phevalin (aureusimine B) production by Staphylococcus aureus biofilm and impacts on human keratinocyte gene expression
Heruth et al. RNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis
ECSP088262A (es) Proteínas de fusión de albúmina
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
NO20061292L (no) Heterosyldiske forbindelser og fremgangsmater for fremstilling og anvendelse derav
BRPI0606803A2 (pt) axmi-018, axmi-020 e axmi-021, uma famìlia de genes de delta-endotoxina e métodos para seu uso
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
EA201201661A1 (ru) Новые аминопиразолохиназолины
EA201200515A1 (ru) Полипептиды и их применение
BR112012010333A2 (pt) peptídeos terapêuticos
HK1134283A1 (en) Arylsulfonamide compounds
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
DE602006020501D1 (de) Synthetische mecp2-sequenz für die proteinersatztherapie
BRPI0714844B8 (pt) molécula de ácido nucleico e seus usos, composição farmaceutica e complexo